GLP-1 for Pre-Diabetics: Preventing Type 2 Diabetes

Introduction

Roughly 98 million American adults have prediabetes, and the CDC estimates 70% will develop type 2 diabetes in their lifetime without intervention. The original Diabetes Prevention Program (DPP) trial established the benchmark in 2002: intensive lifestyle change cut progression by 58% over three years. Metformin cut it by 31%.

The newer data with GLP-1 medications is stronger. STEP 1 (Wilding et al. 2021 NEJM) reported that 84.1% of participants with prediabetes at baseline returned to normoglycemia at 68 weeks on semaglutide 2.4 mg, versus 47.8% on placebo. SURMOUNT-1 (Jastreboff et al. 2022 NEJM) showed that 95.3% of participants with prediabetes reverted to normal glycemia on tirzepatide 15 mg.

Those are unprecedented numbers in a field where prediabetes reversal has been notoriously hard.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Counts as Prediabetes?

Prediabetes is defined by the ADA as a fasting plasma glucose of 100 to 125 mg/dL, a 2-hour oral glucose tolerance test of 140 to 199 mg/dL, or an A1C of 5.7 to 6.4%. Any one of these qualifies.

Quick Answer: 96 million U.S. adults have prediabetes (A1C 5.7 to 6.4%)

About 38% of U.S. adults meet criteria. Only about 19% of them know it. Most people find out from a routine physical lab, not symptoms, because prediabetes is usually silent.

Risk of progression depends on which criterion you cross and how far. An A1C of 6.3 progresses faster than an A1C of 5.8. Adults with both elevated fasting glucose and elevated A1C progress fastest. The DPP placebo arm progressed at about 11% per year, which is the standard reference for untreated progression risk.

How Do GLP-1 Medications Reverse Prediabetes?

Three mechanisms working at once. First, they amplify glucose-dependent insulin secretion, so the pancreas responds more efficiently to meals. Second, they suppress glucagon during hyperglycemia, which cuts hepatic glucose output. Third, weight loss itself improves insulin sensitivity at the muscle and liver level.

STEP 1 sub-analyses show that fasting glucose dropped by about 8 mg/dL on semaglutide independent of weight loss in the first 12 weeks. Then a larger drop comes with the weight loss curve over the following year. By week 68, mean A1C fell 0.45 percentage points from a baseline of 5.7%.

Tirzepatide adds a GIP agonism component on top of GLP-1 action. SURMOUNT-1 reported A1C reductions of 0.5 to 0.6 points in participants with prediabetes at baseline, again from a relatively low starting A1C.

In people with full type 2 diabetes, the same mechanisms produce much larger A1C drops (1.5 to 2.0 points in SUSTAIN and SURPASS programs) because there is more disease to reverse.

How Does This Compare to the Diabetes Prevention Program (DPP)?

DPP set the bar in 2002 at 58% relative risk reduction with intensive lifestyle change. That program was 7% weight loss plus 150 minutes per week of moderate exercise. Metformin produced 31% relative risk reduction in the same trial.

GLP-1 medications produce a higher rate of glycemic normalization, but most of the head-to-head data is short-term. STEP 1 ran 68 weeks. SURMOUNT-1 ran 72 weeks. DPP followed participants for 2.8 years on average, and the DPP Outcomes Study extended that to 15 years.

The 15-year DPP follow-up showed that lifestyle intervention reduced diabetes incidence by 27% over the long haul, with persistent benefit. We do not yet have 15-year GLP-1 data. STEP 5 (Garvey et al. 2022 Nature Medicine) ran 104 weeks and showed sustained weight loss and glycemic improvement, which is the longest published evidence so far.

The honest answer: GLP-1s produce faster, larger short-term effects. Lifestyle change has the longest evidence base. Combined approaches are likely the best.

Should Every Prediabetic Person Consider a GLP-1?

No. Not everyone needs medication. About 30 to 40% of adults with prediabetes can reverse it with 5 to 10% weight loss through diet and exercise alone, based on DPP and Look AHEAD trial data.

GLP-1s become a stronger consideration when one or more of these are true: A1C above 6.0%, prior failed lifestyle attempts, BMI 30 or higher (or 27 with another risk factor), significant family history of type 2 diabetes, gestational diabetes history, or polycystic ovary syndrome.

For someone with an A1C of 5.8 and a BMI of 26, a structured lifestyle program through the CDC National Diabetes Prevention Program is the right first step. For someone with an A1C of 6.3 and a BMI of 34 who has tried and lost weight three times, the calculus shifts toward pharmacotherapy.

A TrimRx free assessment quiz captures the risk factors and lab values that drive this decision.

What Weight Loss Is Needed to Reverse Prediabetes?

Roughly 5 to 7% body weight loss reverses prediabetes in 40 to 60% of people. The DPP threshold was 7%. Look AHEAD confirmed similar numbers. Larger weight losses produce higher reversal rates.

DiRECT (Lean et al. 2018 Lancet) studied weight loss in people with established type 2 diabetes, not prediabetes, but the gradient is informative. At 12 months, 46% of participants achieved diabetes remission, and remission rates scaled with weight loss: 7% of those who lost less than 5 kg achieved remission, 34% of those who lost 5 to 10 kg, 57% of those who lost 10 to 15 kg, and 86% of those who lost 15 kg or more.

STEP 1 produced 14.9% weight loss on semaglutide. SURMOUNT-1 produced 20.9% on tirzepatide 15 mg. Both put almost all prediabetic participants well past the threshold.

What Is the Right A1C Goal on a GLP-1?

Below 5.7% is the formal definition of normoglycemia. Most prediabetic patients on GLP-1s can hit it. The clinically meaningful threshold is also stable, sustained reduction. An A1C that drops from 6.2 to 5.6 and stays there for two years is more meaningful than one that drops to 5.4 and rebounds.

The ADA Standards of Care (2024) recommend A1C testing every 3 to 6 months in patients undergoing weight loss therapy. Once weight is stable and glycemia is normal, annual monitoring is reasonable.

Fasting glucose tracking can be useful early. A continuous glucose monitor for a 2-week period at baseline and after 6 months gives a more complete picture than A1C alone, particularly for catching postprandial spikes that the A1C might miss.

Key Takeaway: Tirzepatide reverted 95.3% to normoglycemia in SURMOUNT-1 over 72 weeks

How Long Does Someone Need to Stay on a GLP-1 to Prevent Diabetes?

The honest answer: probably indefinitely if the goal is sustained prevention. STEP 4 (Rubino et al. 2021 JAMA) showed that stopping semaglutide led to two-thirds weight regain at 52 weeks, and glycemic gains regressed with it.

The DPP Outcomes Study suggests that the lifestyle benefits decay more slowly. Participants who maintained habits kept much of the diabetes prevention effect at 15 years. GLP-1 data does not extend that far.

A reasonable strategy: use GLP-1 to get into the normoglycemic range and lose the weight, build deep lifestyle changes during that window, and then have a conversation with the clinician about dose reduction or discontinuation versus continued therapy at a lower dose. Some patients will need lifelong therapy. Others will be able to maintain on lifestyle alone after the reset.

What About Combining GLP-1s with Metformin?

Reasonable in selected patients. Metformin remains the first-line oral agent for type 2 diabetes prevention with the strongest long-term data. The DPP showed 31% diabetes risk reduction over 3 years, and follow-up data extended that.

For adults with prediabetes plus PCOS, prior gestational diabetes, or BMI over 35, the ADA recommends considering metformin. Adding a GLP-1 produces additive A1C reduction. The SUSTAIN-3 trial in patients already on metformin showed semaglutide cut A1C an additional 1.5 points.

The two drugs hit different mechanisms. Metformin lowers hepatic glucose output. GLP-1s amplify insulin secretion, suppress glucagon, and drive weight loss. They do not interact pharmacokinetically, and the combined GI side effect profile is manageable when titrated carefully.

Are There Risks Specific to Using GLP-1s in Non-diabetic Prediabetic Patients?

The risk profile is the same as in obesity treatment, which is well-characterized. The most common adverse events are GI: nausea (44% on semaglutide 2.4 mg in STEP 1), diarrhea (30%), constipation (24%), vomiting (24%).

Hypoglycemia is rare in non-diabetic populations because GLP-1 insulin release is glucose-dependent. The pancreas does not over-secrete insulin when blood sugar is normal. SELECT (Lincoff et al. 2023 NEJM), which enrolled non-diabetic patients, reported severe hypoglycemia in 0.1% on semaglutide versus 0.1% on placebo.

Pancreatitis risk in trials was 0.2 to 0.3% per year, with no clear excess versus placebo when pooled across STEP and SUSTAIN programs. Gallstones increased modestly, consistent with rapid weight loss in any setting.

Thyroid C-cell tumor risk is a labeled contraindication in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome. The rodent signal has not been confirmed in humans, but the label remains.

What Does a Real Prevention Plan Look Like?

A combined approach. Medication to drive weight loss and glycemic correction, with structured lifestyle work that lasts beyond the prescription.

The CDC National Diabetes Prevention Program is a 12-month structured intervention with 16 weekly sessions and 6 monthly maintenance sessions, available in person or online, often covered by insurance. The protocol targets 5 to 7% weight loss and 150 minutes per week of moderate activity.

For a prediabetic patient on a GLP-1, the medication makes the weight loss easier. The structured program builds the habits that protect against rebound. Resistance training twice a week prevents the lean mass loss that comes with rapid caloric reduction.

Sleep, stress, and alcohol matter. Insulin resistance is worsened by short sleep (less than 6 hours), chronic stress, and regular alcohol use above 7 drinks per week. These do not need to be perfect, but they cannot be ignored.

Bottom line: GLP-1s lower fasting glucose by 25 to 40 mg/dL and A1C by 0.8 to 1.5% in non-diabetic populations

FAQ

Will Insurance Cover a GLP-1 for Prediabetes Alone?

Generally no. Commercial insurance covers GLP-1s for type 2 diabetes (Ozempic®, Mounjaro®) and obesity (Wegovy®, Zepbound®). Prediabetes alone is not a labeled indication. Coverage often requires a BMI over 30 (or 27 with comorbidities) for the obesity indication.

How Quickly Does A1C Drop on a GLP-1?

A1C lags by 6 to 12 weeks because it reflects average glucose over the prior 3 months. Most patients see a meaningful drop by the 12-week recheck and the full effect by 6 months.

Can I Switch From Metformin to a GLP-1?

Possible, depending on the situation. For a prediabetic patient on metformin alone who tolerates it, adding a GLP-1 may be better than switching. For someone with GI intolerance to metformin, switching to a GLP-1 is reasonable. Talk to a clinician about the specific situation.

What If My A1C Is Borderline (5.7 to 5.8)?

Borderline prediabetes responds well to lifestyle change alone in most cases. A 7% weight loss through structured diet and exercise produces normalization in 40 to 50% of cases at this A1C range. GLP-1s are a stronger consideration when A1C is 6.0 or higher or when prior lifestyle attempts have failed.

Does the Diabetes Prevention Effect Persist After Stopping the GLP-1?

Partially. STEP 4 showed substantial weight regain after discontinuation, and glycemic gains regressed with it. The effect of behavioral changes built during therapy can persist, but the pharmacologic effect does not.

Is Tirzepatide Better Than Semaglutide for Prediabetes?

SURMOUNT-1 produced higher normoglycemia rates (95.3% vs 84.1% in STEP 1), but the trials were not head-to-head. SURPASS-2 (Frias et al. 2021 NEJM) directly compared the two in type 2 diabetes and tirzepatide produced larger A1C and weight reductions. For most patients, either is effective and the choice often comes down to access, cost, and tolerability.

Should I Tell My Doctor I Am Taking a Compounded GLP-1?

Yes, always. Your primary care or endocrinology clinician needs to know to coordinate lab monitoring, adjust other medications if needed, and avoid duplicate prescribing. A TrimRx clinician communicates with the patient throughout, but the broader care team should also be informed.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.